inclusion criteria: * history of hospitalization for covid-19 infection documented with positive pcr or positive serology in the previous 2 to 12 months * lung opacities on hrct involving more than 10% of the lung volume, with fibrotic features * dlco≤ 70% of the predicted value

inclusion criteria: * history of hospitalization for covid-19 infection documented with positive pcr or positive serology in the previous 2 to 12 months * lung opacities on hrct involving more than 10% of the lung volume, with fibrotic features * dlco≤ 70% of the predicted value

inclusion criteria: - history of hospitalization for covid-19 infection documented with positive pcr or positive serology in the previous 2 to 12 months - lung opacities on hrct involving more than 10% of the lung volume, with fibrotic features - dlco≤ 70% of the predicted value

inclusion criteria: - history of hospitalization for covid-19 infection documented with positive pcr or positive serology in the previous 2 to 12 months - lung opacities on hrct involving more than 10% of the lung volume, with fibrotic features - dlco≤ 70% of the predicted value

inclusion criteria: - history of hospitalization for covid-19 infection documented with positive pcr or positive serology in the previous 2 to 6 months - lung opacities on hrct involving more than 10% of the lung volume, with fibrotic features - dlco≤ 70% of the predicted value

inclusion criteria: - history of hospitalization for covid-19 infection documented with positive pcr or positive serology in the previous 2 to 6 months - lung opacities on hrct involving more than 10% of the lung volume, with fibrotic features - dlco≤ 70% of the predicted value